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The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository makes data and biospecimens from NIDDK-funded research available to the broader scientific community. It thereby facilitates: the testing of new
hypotheses without new data or biospecimen collection; pooling data across several studies to increase statistical power;
and informative genetic analyses using the Repository’s well-curated phenotypic data. This article describes the initial
database plan for the Repository and its revision using a simpler model. Among the lessons learned were the trade-offs
between the complexity of a database design and the costs in time and money of implementation; the importance
of integrating consent documents into the basic design; the crucial need for linkage files that associate biospecimen IDs
with the masked subject IDs used in deposited data sets; and the importance of standardized procedures to test the
integrity data sets prior to distribution. The Repository is currently tracking 111 ongoing NIDDK-funded studies many of
which include genotype data, and it houses over 5 million biospecimens of more than 25 types including serum, plasma,
stool, urine, DNA, red blood cells, buffy coat and tissue. Repository resources have supported a range of biochemical,
clinical, statistical and genetic research (188 external requests for clinical data and 31 for biospecimens have been approved
or are pending). Genetic research has included GWAS, validation studies, development of methods to improve statistical
power of GWAS and testing of new statistical methods for genetic research. We anticipate that the future impact of the
Repository’s resources on biomedical research will be enhanced by (i) cross-listing of Repository biospecimens in additional
searchable databases and biobank catalogs; (ii) ongoing deployment of new applications for querying the contents of the
Repository; and (iii) increased harmonization of procedures, data collection strategies, questionnaires etc. across both
research studies and within the vocabularies used by different repositories.
Database URL: http://www.niddkrepository.org
.............................................................................................................................................................................................................................................................................................

Background
In 2003, the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) at the National Institutes
of Health (NIH) established data, biosample and genetic

repositories to increase the impact of current and previously funded NIDDK studies by making their data and biospecimens available to the broader scientific community
(see www.niddkrepository.org). These repositories, collectively known as the ‘NIDDK Central Repository’, enable
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scientists not involved in the original study to test new
hypotheses without new data or biospecimen collection,
and the Repository provides the opportunity to pool data
across several studies to increase the power of statistical
analyses. In addition, most NIDDK-funded studies collect
genetic biospecimens and some carry out high-throughput
genotyping, making it possible for other scientists to use
Repository resources to perform informative genetic analyses using well-curated phenotypic data.
In this article, we describe: the ambitious initial design of
the Repository; the subsequent simplification of that design
to better accommodate the needs of users and the constraints of available resources; the current status of the
Repository; the data and biospecimens offered to researchers; and examples of the use made of Repository resources
for biomedical research. We conclude by describing some of
the key lessons we learned in the evolution of the
Repository and the bioinformatic enhancements we are
currently making to the Repository.

An ambitious database proposal in 2002
We envisioned that the NIDDK Data Repository would be
a large system consisting of primary databases in the private domain (shown in Exhibit 1 as NIDDK Data Repository),
and support databases in the public domain (shown
in Exhibit 1 as NIDDK Web Databases). Creating databases in both domains was deemed necessary for providing
security and accessibility for authorized project and
public users.
The primary databases in the private domain were
planned to include a project management (Control) database and individual study databases. The Control database
(Control_DB) was intended to have tables and views (stored
queries) that would help manage project functions, track
and manage study databases and provide information for
reports. The study databases (Study_DB) was intended to
have tables and views that contain the study data, code
books and information that will assist in database management, track researcher requests and provide data in response to researcher requests.
The support databases were intended to include any
databases necessary to support the public website. It was
anticipated that a primary database (NIDDK_Web_DB)
would have the tables and views that support the website’s
ability to inform researchers of available studies, manage
researcher access to the private pages, support a hosted
user forum and support researcher requests for data.
Additional study databases (Study_Pub_DB) would be created to contain study–specific tables for codebooks, documentation lists, user request logs, etc. These databases
would be used to provide study–specific information and
to facilitate methods for researcher requests for data based
on available fields.

Revision of design
Our initial plan was ambitious, complex and expensive.
Upon the award of the contracts to build the Repository
and supporting database tools, we conducted a requirements analysis that considered both NIDDK’s and the
scientific community’s interests and needs. This analysis
concluded that our proposed approach was inappropriate
for a number of reasons the most important being development cost and lag time in bringing the Repository online.
This formal review of the perspectives of all repository
stakeholders (i.e. NIDDK, the research centers contributing
the data, the subjects providing the data and the data consumers) identified the following core requirements for developing and maintaining a large repository of the scale we
envisioned.
(1) A public website to support communication functions
including informing users about: how to identify
the contents of the Repository, how to obtain repository products, how to contribute products to the
Repository and how to access Repository personnel.
(2) A screening process for data and specimen requesters
to control access to Repository resources. Accordingly,
if a user was interested in obtaining Repository products, they would be obligated to provide a research
plan that identifies how the products are to be used
and this plan would be reviewed and approved or
disapproved by NIDDK.
(3) A hierarchal view of available data, biospecimens and
supporting documentation. This hierarchy begins with
an overview of the study that identifies its purpose,
outcomes and design features; a detailed description
of how the study operated (protocol and MOOP); and
the nuts and bolts of how the data were captured
(data collection forms).
(4) A mechanism for supplying information on subsets of
study variables (and therefore data) since a non-trivial
percentage of those variables would be of little general interest to potential users.
(5) Rigorous procedures to insure that data distributed by
the Repository were checked for completeness, accuracy and compliance with HIPAA regulations.

A simpler design for the Repository
To fulfill these requirements, we revised our plan for the
design and implementation of the Repository to include:
 A standard template for the documentation for each
study that included: (i) a general description of the
study, (ii) manuals of Operations and Protocols (descriptions of the procedures used to collect clinical data and
samples), (iii) all Data Capture Forms used in collecting
clinical data, (iv) Data Descriptions (including summary

.............................................................................................................................................................................................................................................................................................
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Exhibit 1. Initial Plan for NIDDK Data Repository.

statistics on distributions of variables and SAS variable
descriptions and (v) Links to the study’s publications.
 Placement of data and biospecimens in different physical locations and restricted domains from their documentation. The data (in contrast to data descriptions) were
resident in the data archive section of the Repository
and were accessible only to Repository staff. These
data were only distributed to approved researchers.

This meant that there would be reduced security issues
involving unapproved access to the data because these
data would be behind the Repository firewall. The documentation was also part of the data archive but unlike
the archive it was viewable from the public component
of the website.
 Development of a series of semi-automated applications that permitted users to submit requests for data

.............................................................................................................................................................................................................................................................................................
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and samples online. These processes were modified
over time to support higher levels of automation.
 A data curation process that provided a standard directory layout for organizing the data into data archives
and adding documentation to promote usability.
 Development of a pre-release data checking procedure
that selects published peer-reviewed manuscripts from
a study and independently reproduces tables and statistical analyses using the data deposited in the repository. This process helps insure the integrity of the data
distributed by the Repository.
Over time—as the number of studies housed at the
Repository has grown—we have recognized an additional
requirement for efficient ways of searching the Repository
contents and retrieving relevant documents. New tools for
that purpose are being rolled out during 2011. (In a later
section of this article, we describe these tools.)

Major components of the Repository in 2011
At present the NIDDK Central Repository has five major
components:
 an archive of clinical data and documentation from
NIDDK-sponsored studies;
 a collection of biospecimens and an associated database
that identifies specimens collected from ongoing and
completed studies funded by NIDDK and links them to
the associated phenotypic data;
 a Web portal that makes study-specific information
within the Repository easily viewable and that accepts
electronic requests for biospecimens and data; and
 a collection of genotyping data from genome-wide association studies (GWAS) and sequencing studies housed at
the National Center for Biotechnology Information’s
(NCBI’s) database of Genotypes and Phenotypes (dbGaP;
see http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap).
 a library of study- and site-specific consent forms
that govern the release and use of study data and
specimens.

Status of Repository
Studies
As of 9 March 2011, the Repository was tracking 111
NIDDK-funded studies. From these studies, the Repository
offers resources for clinical, biochemical, statistical and genetic research especially in the areas of diabetes, kidney disease, liver disease and inflammatory bowel disease.
At present, the Repository offers clinical data from 29 completed NIDDK-funded studies—15 of which currently offer
biospecimens and 7 of which have available genotype data.
Table 1 provides descriptions of these studies, the specimens available from each study, and the number of

subjects enrolled. Since there is substantial variability in
the types of clinical data available from each study, it is
not feasible to summarize it in this article. Suffice it to
say that the collection of clinical data is large, diverse and
carefully curated. As an example of the studies included in
this collection, we would note the DCCT-EDIC study which is
continuing to follow a cohort of Type 1 diabetic patients
recruited in 1983. The clinical data include the results of
physical examinations with extensive measurements at
regular intervals of retinopathy, nephropathy, neuropathy
and cardiovascular status along with metabolic and lipid
profiles. (Biospecimens available from DCCT-EDIC include
DNA, plasma, RNA, serum, urine and peripheral blood
mononuclear cells [PBMC].). (Samples may include multiple
aliquots of the same unique specimens.)
A complete catalog of all of the clinical data sets available from the Repository can be found at https://www
.niddkrepository.org/niddk/jsp/public/dataset.jsp

Biospecimens
The Repository houses biospecimens both from studies for
which we have clinical data sets and studies that have not
yet deposited clinical data sets. As a result, the number
and range of Repository biospecimens is substantially
greater than those shown in Table 1. In Table 2, we present
a tabulation of the different types of biospecimens available from the Repository and the studies that contributed
each type of specimen. It will be seen from Table 2 that the
Repository offers more than 20 different types of biospecimens with over 5 million samples in storage. The most
common biospecimens are serum, plasma, urine, DNA and
buffy coat, plus the more than 470 000 stool samples collected by The Environmental Determinants of Diabetes in
the Young (TEDDY) study.

Use of Repository
Since 2004, the Repository website (http://www.niddkrepository.org) has provided the public with access to details of
all studies included in the NIDDK Central Repository, including study summaries, protocols, manuals of operation, data
collection forms and lists of publications, available data sets
and biospecimens. In addition, the Website allows investigators to apply electronically for access to data and biospecimens. Although the Repository Website provides an
efficient and easily accessible portal for obtaining information on archived studies, Repository staff and statisticians
frequently provide scientists with additional information
prior to formal requests for data or biospecimens. So, for
example, a researcher might send the Repository an e-mail
saying: ‘I understand that a subset of patients in the
Modification of Diet in Renal Disease (MDRD) study had
polycystic kidney disease (PKD). How can I obtain information regarding the number of PKD patients in the MDRD
database?’ The Repository has responded to numerous such

.............................................................................................................................................................................................................................................................................................
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Study

Adult Living Donor Liver
Transplantation

The African American Study
of Kidney Disease and
Hypertension Study

Acute Renal Failure Trial Network

Boston Area Community Health
Study

Behavior Enhances Drug
Reduction of Incontinence

Comprehensive Dialysis Study

Chronic Prostatitis Collaborative
Research Network Cohort Study

Chronic Prostatitis Collaborative
Research Network Clinical Trial

Consortium for Radiologic
Imaging Studies of PKD

Diabetes Prevention Program

Diabetes Prevention Trial—Type 1

Epidemiology of Diabetes
Interventions and Complications

The Type 1 Diabetes Control
and Complications Trial

Family Investigation of
Nephropathy and Diabetes

Acronym

A2ALL

AASK

ATN

BACH

BE-DRI

CDS

CPCRN

CPCRN RCT #1

CRISP

DPP

DPT-1

EDIC

DCCT

FIND

Type 2 diabetes, Kidney disease

Type 1 diabetes, Coronary heart
disease, Kidney disease,
Neuropathy, Retinopathy

Type 1 diabetes, Coronary heart
disease, Kidney disease,
Neuropathy, Retinopathy

Type 1 diabetes,

Type 2 diabetes, Impaired glucose
tolerance

Kidney disease, PKD

Prostatitis, Chronic pelvic pain

Prostatitis, Chronic Pelvic Pain

Kidney disease, Dialysis

Incontinence

Urogynecologic symptoms,
Incontinence, Interstitial cystitis,
Chronic pelvic pain, Prostatitis,
Hypogonadism, Sexual
dysfunction

Kidney disease, End stage kidney
disease

Kidney disease, Hypertension

Liver disease, End stage liver
disease, kidney disease

Conditions

Table 1. Studies currently offering clinical data from the NIDDK Central Repository

(i) Family-based
Linkage analysis,
and (ii) genetic
case-control study
using mapping by
admixture linkage
disequilibrium
(MALD)

Clinical trial

Longitudinal
Follow-up of
Participants
in DCCT

Clinical trial

Clinical trial

Prospective cohort
study

Clinical trial

Prospective cohort
study

Prospective cohort
study

Clinical trial

Epidemiologic
survey

Clinical trial

Clinical trial

Retrospective
records review

Study type

.............................................................................................................................................................................................................................................................................................
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9031 including
family dyads and
triads for linkage
analysis

Yes

DNA, serum, urine,
whole blood

1297 active in 2008a

711

3819

241

272

488

1677

4043 screened,
307 randomized

5506

1124

2802 screened,
1094 randomized

819

Sample sizes

1441

Yes

Yes

Genotype
available

DNA, Plasma, PBMC,
RNA, Serum

DNA, Plasma, serum,
urine

DNA, Plasma, Serum

DNA, Plasma

DNA, plasma,
serum, urine,
whole blood

PBMC, plasma,
serum

buffy coat, serum,
urine

DNA, serum, tissue,
whole blood

Biospecimens
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The Genetics of Kidneys in
Diabetes

The Hepatitis C Antiviral
Long-term Treatment
against Cirrhosis

Hemodialysis Study

Inflammatory Bowel Disease
Genetics

Interstitial Cystitis Clinical Trail # 1

Interstitial Cystitis Clinical Trail # 2

Interstitial Cystitis cohort study

Liver Transplantation Database

Liver Transplantation Database
Follow Up

Modification of Diet in Renal
Disease

Medical Therapy of Prostatic
Symptoms

National Analgesic Nephropathy
Study

The Stress Incontinence Surgical
Treatment Efficacy Trial

Type 1 Diabetes Genetics
Consortium

Viral Resistance to Antiviral
Therapy of Chronic Hepatitis C

GoKind

HALT-C

HEMO

IBD

ICCTG RCT#1

ICCTG RCT#2

ICDB

LTD

LTD2

MDRD

MTOPS

NANS

SISTEr

T1DGC

Virahep-C

Hepatitis C, Liver disease

Type 1 diabetes

Urinary incontinence, Stress
urinary incontinence

Kidney disease, End-stage renal
disease

Benign prostatic hyperplasia,
Enlarged prostate

Kidney disease

Liver disease, End stage liver
disease

Liver disease, End stage liver
disease

Interstitial cystitis, Chronic pelvic
pain

Interstitial cystitis, Chronic pelvic
pain

Interstitial cystitis, Chronic pelvic
pain

Inflammatory bowel disease,
Crohn’ s disease

Kidney disease, Dialysis

Hepatitis C, Liver disease, Cirrhosis

Type 1 diabetes, Kidney disease

Conditions

Clinical trial

Genetic case–control
study

Clinical trial

Case–control study

Clinical trial

Two clinical trials

Prospective cohort
study

Prospective cohort
study

Clinical trial

Clinical trial
(Pilot Study)

Genetic case–control
study

Clinical trial

Clinical trial

Genetic case–control
study

Study type

DNA, PBMC, plasma,
RNA, Serum

DNA, plasma, serum

b

401

14 350, including
sib-pairs and trios

655

240 ESRD cases
206 controls

c

585 and 255

728 survivors of
LTD cohort of 916

916

265 randomized

121

4761 including
cases, controls
and triosb

1846

1145

3079 including both
singletons and
trios

Sample sizes

3047

Yes

Yes

Yes

Yes

Genotype
available

serum

buffy coat, plasma,
serum, urine

tissue

urine

urine

DNA, serum,
whole blood

serum

tissue

DNA, Plasma, serum,
urine

Biospecimens

Source: www2.bsc.gwu.edu/bsc/oneproj.php?pkey=10 (18 July 2011, date last accessed).
As of November 2007; Source: www.niddkrepository.org/niddk/jsp/public/IBD/IBDMetadata.jsp (18 July 2011, date last accessed).
c
Digitized CT scans of kidneys are available for 207 EDRD subjects and 26 normal cases.

a

Study

Acronym

Table 1. Continued
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Table 2. Biospecimens currently banked at the NIDDK Repositorya
Specimenb

Studiesc

No. of
Specimens

Bile

BARC, PALF

Blood

CLiC, CRISP II, DAC, FHN, FSGS/FONT_FONT, FSGS/FONT_FONT II, FSGS/FONT_FSGS, HALT
PKD II, HALT PKD I, HBRN, PALF, RIVUR_CUTIE, RIVUR_RIVUR, SIGT, TrialNet_TN07 Oral
Insulin

156

Blood, Peripheral
Blood Smear

TEDDY

Buffy coat

AASK_MAIN, AASK_PILOT, CRIC, FAVORIT, MDRD, SIGT, TEDDY

80 936

Cell Pack DNA

T1DGC

17 013

Cells

Virahep-C

DNA

DPP, DPT1_Denver, DCCT-EDIC, FIND, IBD, TrialNet, TrialNet_TN01 NH, TrialNet_TN02
MMF/DZB

Extracted mRNA

TEDDY

Fibroblasts, skin

PALF

Frozen plasma

AASK_COHORT, AASK_MAIN

Hair

CKiD

Nail clipping

CKiD, TEDDY

24 252

6924

74
131 535
528
165
9226
399
5512

Nasal swab

TEDDY

32 748

Peripheral blood
mononuclear
cells (PBMC)

CDS, CITC_CIT-02, CITC_CIT-03, CITC_CIT-04, CITC_CIT-0501, CITC_CIT-07, CITC_CIT-99,
TEDDY, TrialNet, TrialNet_TN01 NH, TrialNet_TN02 MMF/DZB, TrialNet_TN04 T cell
assay validation, TrialNet_TN05 antiCD20, TrialNet_TN07 Oral Insulin, TrialNet_TN08
GAD new onset, TrialNet_TN09 CTLA4-Ig, TrialNet_TN12 Metabolic Control, Virahep-C

50 577

Plasma

AALF-AALI, AALF-AALF, AASK_COHORT, ASSESS-AKI, BARC, CDS, CITC_CIT-02, CITC_CIT03, CITC_CIT-04, CITC_CIT-0501, CITC_CIT-06, CITC_CIT-07, CITC_CIT-99, CKiD, CLiC, CRIC,
CRISP II, CRISP I, DAC, DILIN_Prospective, DILIN_Retrospective, DPP, DPT1_Seattle,
FAVORIT, FBEC, FHN, FSGS/FONT_FONT, FSGS/FONT_FONT II, FSGS/FONT_FSGS, GoKind,
GpCRC, HALT PKD II, HALT PKD I, HBRN, HFMC, LABS, MDRD, NASH,
NASH_NAFLD_A_DB2, NASH_NAFLD_DB, NASH_NAFLD_P_DB2, NASH_PIVENS,
NASH_TONIC, PALF, PEDS-C, RIVUR_RIVUR, SIGT, SyNCH PK, SyNCH, T1DGC, TEDDY,
Teen-LABS, TrialNet, TrialNet_TN01 NH, TrialNet_TN02 MMF/DZB, TrialNet_TN05
antiCD20, TrialNet_TN07 Oral Insulin, TrialNet_TN08 GAD new onset, TrialNet_TN09
CTLA4-Ig, TrialNet_TN12 Metabolic Control, TrialNet_TN14 Anti-IL-1 Beta, Virahep-C

1 455 363

Red Blood Cells

FAVORIT, SIGT, TEDDY

RNA

CITC_CIT-02, CITC_CIT-03, CITC_CIT-04, CITC_CIT-0501, CITC_CIT-07, CITC_CIT-99,
TrialNet_TN01 NH, TrialNet_TN02 MMF/DZB, Virahep-C

95 669
9536

Saliva

TEDDY

Serum

A2ALL, AALF-AALI, AALF-AALF, AASK_COHORT, AASK_MAIN, AASK_PILOT, ASSESS-AKI,
BARC, CAMUS, CDS, CITC_CIT-02, CITC_CIT-03, CITC_CIT-04, CITC_CIT-0501, CITC_CIT-06,
CITC_CIT-07, CITC_CIT-99, CKiD, CLiC, CRIC, CRISP II, CRISP I, DAC, DILIN_Prospective,
DPT1_Seattle, DPT1_Florida, DPT1_Boston, FAVORIT, FHN, FSGS/FONT_FONT, FSGS/
FONT_FONT II, FSGS/FONT_FSGS, GoKind, GpCRC, HALT PKD II, HALT PKD I, HBRN,
HEMO, HFMC, IBD, LABS, MDRD, MTOPS, NASH, NASH_NAFLD_A_DB2,
NASH_NAFLD_DB, NASH_NAFLD_P_DB2, NASH_PIVENS, NASH_TONIC, PALF, PEDS-C,
RIVUR_CUTIE, RIVUR_RIVUR, SyNCH, T1DGC, TEDDY, Teen-LABS, TrialNet,
TrialNet_TN01 NH, TrialNet_TN02 MMF/DZB, TrialNet_TN09 CTLA4-Ig, TrialNet_TN14
Anti-IL-1 Beta, Virahep-C

3994

Stool

TEDDY

Stool (PBS washed)

TEDDY

Tissue

A2ALL, AALF-AALI, AALF-AALF, BARC, CLiC, DILIN_Prospective, HBRN, HFMC, ICDB, NASH,
NASH_NAFLD_A_DB2, NASH_NAFLD_DB, NASH_NAFLD_P_DB2, NASH_PIVENS, PALF

2 132 215

470 863
1770
55 785

(continued)
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Table 2. Continued
Specimenb

Studiesc

Urine

AALF-AALI, AALF-AALF, AASK_COHORT, AASK_MAIN, AASK_PILOT, ASSESS-AKI, BARC,
CKiD, CLiC, CRISP II, DILIN_Prospective, DCCT-EDIC, FAVORIT, FSGS/FONT_FONT, FSGS/
FONT_FONT II, FSGS/FONT_FSGS, GoKind, ICCRN_ICCRN RCT #2, ICCRN_ICCTG RCT#1,
LABS, MDRD, MaGIC, PALF, RICE, RIVUR_CUTIE, RIVUR_RIVUR, SyNCH PK, SyNCH,
Teen-LABS, UITN_TOMUS, UITN_ValUE, CRIC, CRISP I, MDRD, HALT PKD I, HALT PKD II,
AALF-AALF, PALF, HALT PKD I, HALT PKD II, CRISP II, MDRD, CRIC, CRISP I, HALT PKD I,
HALT PKD II

No. of
Specimens
432 315

Whole blood DNA

T1DGC

326

Whole genomeamplified DNA

T1DGC

1436

Total

5 019 951

a

Biospecimens from some studies are available for sharing now; others will be available in the future. For availability dates, see www
.niddkrepository.org/niddkdocs/resources/Sample_Availability_Dates.pdf.
b
Table excludes specimens, if N < 10, and a few specimen types of indeterminate status.
c
Studies are: A2ALL, Adult Living Donor Liver Transplantation; AALF, Adult Acute Liver Failure Study Group; AASK, The African American
Study of Kidney Disease and Hypertension Study; ASSESS-AKI, ASsessment, Serial Evaluation and Subsequent Sequelae in Acute Kidney
Injury; BARC, Biliary Atresia Research Consortium; CAMUS, Complementary and Alternative Medicine for Urological Symptoms; CDS,
Comprehensive Dialysis Study; CITC, Clinical Islet Transplantation Consortium, substudies; CKiD, Cohort Study of Kidney Disease; CLiC,
Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis; CRIC, Chronic Renal Insufficiency Cohort Study; CRISP, Consortium for
Radiologic Imaging Studies of PKD, 1 & 2; DAC, Dialysis Access Consortium; DCCT-EDIC, Diabetes Control and Complications Trial and
Epidemiology of Diabetes Interventions and Complications follow-up study; DILIN, DILIN 1: Idiosyncratic Liver Injury Associated with
Drugs, Prospective and Retrospective; DPP, Diabetes Prevention Program; DPT-1, Diabetes Prevention Trial–Type 1, site specific; FAVORIT,
Folic Acid for Vascular Outcome Reduction in Transplantation Trial;
FBEC, Familial Barrett’s Esophagus; FHN, Frequent Hemodialysis Network; FSGS/FONT, Focal Segmental Glomerulosclerosis, substudies;
GoKind, The Genetics of Kidneys in Diabetes; GpCRC, Gastroparesis Registry; HALT PKD, The Polycystic Kidney Disease Treatment
Network, 1 & 2; HBRN, Hepatitis B Research Network; HEMO, Hemodialysis Study; HFMC, Hemodialysis Fistula Maturation Consortium;
IBD, Inflammatory Bowel Disease Genetics; ICCRN RCT 1 & 2, Interstitial Cystitis Clinical Resarch Network, Trials 1 & 2; ICDB, Interstitital
Cystitis cohort study; LABS, Longitudinal Assessment of Bariatric Surgery; MaGIC, Maryland Genetics of Intersitial Cystitis Study; MDRD,
Modification of Diet in Renal Disease; MTOPS, Medical Therapy of Prostatic Symptoms; NASH, Nonalcoholic Steatohepatitis Clinical
Research Network, substudies; PALF, Pediatric Acute Liver Failure; PEDS-C, Pegylated Interferon +/– Ribavirin for Children with HCV;
RICE, RAND Interstitial Cystitis Epidemiology Study, substudies; RIVUR, Randomized Intervention for Children with VesicoUreteral Reflux;
SIGT, Screening for Impaired Glucose Tolerance; Synch, Silymarin Trial for Hepatitis C and NASH, substudies; T1DGC, Type 1 Diabetes
Genetics Consortium; TEDDY, Consortium for Identification of Environmental Triggers of Type 1 Diabetes; Teen-LABS, Adolescent
Bariatrics: Assessing Health Benefits & Risks; TrialNet, TrialNet, substudies; UITN, Urinary Incontinence Treatment Network, substudies;
Virahep-C, Viral Resistance to Antiviral Therapy of Chronic Hepatitis C.

requests for detailed information. Between 2008 and 2010,
an average of 28 such requests were received annually via
the ‘Ask the Repository’ link on the Repository’s Website.
Additional requests were received via the NIDDK telephone
help line, the ‘Contact Us’ page of the Repository Website,
and by e-mails sent directly to Repository staff.
As of 9 March 2011, a total of 188 external requests
for archived data sets and 31 external requests for biospecimens either have been approved or are pending. The
number of requests has increased over time as the
Repository has become better known in relevant scientific
communities. In the Repository’s first 2 years of operation
(2003–04), there were no approved data set or biospecimen
requests; by 2010 requests had increased to an annual rate
of 31.
As Table 3 shows, there has been substantial variation in
the popularity of data sets and biospecimens from different

studies. The most frequently requested data sets involved
studies of type 1 and type 2 diabetes. DCCT/EDIC ranks first
in popularity, with 42 approved or pending requests for
data and biospecimens from this landmark study of type
1 diabetes. The Diabetes Prevention Program for type 2
diabetes ranks second, with 21 approved or pending requests for data sets. Data sets and biospecimens from the
Type 1 Diabetes Genetics Consortium (T1DGC; 20 requests)
and Genetics of Kidneys in Diabetes (GoKinD; 13 requests)
rank third and seventh, respectively. In addition, the
Diabetes Prevention Trial of Type 1 Diabetes (DPT-1) ranks
ninth (10 requests). These diabetes studies accounted for
almost one-half (106 of 219) of the approved requests for
Repository data sets and biospecimens.
Studies of renal disease were the second most requested
category of data sets and biospecimens. These included
the MDRD study (19 requests); the African American
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Table 3. Frequency in rank order of approved and pending requests for data sets and biospecimens in NIDDK Data Repository
(as of 9 March 2011)
Rank

Acronym

Study title

Data
requests

Specimen
requests

Total

1

DCCT/EDIC

Type 1 Diabetes Control and Complications Trial & Epidemiology
of Diabetes Interventions and Complications Follow-up

36

6

42

2

DPP

Diabetes Prevention Program

21

0

21

3

T1DGC

Type 1 Diabetes Genetics Consortium

18

2

20

4

MDRD

Modification of Diet in Renal Disease

18

1

19

5

VIRAHEP-C

Viral Resistance to Antiviral Therapy of Chronic Hepatitis C

9

5

14

6

HEMO

Hemodialysis Study

11

3

14

7

GoKinD

Genetics of Kidneys in Diabetes

10

3

13

8

CRISP

Consortium for Radiological Imaging Studies of Polycystic Kidney Disease

10

3

13
10

9

DPT-1

Diabetes Prevention Trial of Type 1 Diabetes

8

2

10

AASK

The African American Study of Kidney Disease and Hypertension Study

9

0

9

11

MTOPS

Medical Therapy of Prostatic Symptoms

8

0

8

12

ICDB

Interstitial Cystitis Data Base

6

1

7

13

LTD

Liver Transplantation Database

6

0

6

14

ATN

The Acute Renal Failure Trial Network

5

0

5

15

IBDGC

Inflammatory Bowel Disease Genetics Consortium

4

0

4

16

HALT-C

Hepatitis C Antiviral Long-term Treatment against Cirrhosis

3

0

3

17

LTD-Follow-up

Liver Transplantation Database Follow-up

2

0

2

18

NANS

National Analgesic Nephropathy Study

2

0

2

19

AALF

Adult Acute Liver Failure Triala

0

2

2

20

CKiD

Prospective Cohort Study of Kidney Disease in Children

0

2

2

21

BACH

Boston Area Community Health Study

1

0

1

22

PROBE

Prospective Database of Infants with Cholestasis

0

1

1

23

SISTEr

The Stress Incontinence Surgical Treatment Efficacy Trial

1

0

1

188

31

219

Total approved and pending requests

Tabulation from NIDDK Central Repository Web site on 9 March 2011. The numbers in Table 1 reflect only approved external or pending
requests not including requests for NIDDK ancillary studies or internal requests from members of study consortia.
a
The Web site for this study uses the acronym ‘ALF’. We use AALF and PALF to distinguish the adult and pediatric trials.

Study of Kidney Disease and Hypertension (AASK; nine requests); the Hemodialysis Study (HEMO; 14 requests); the
Consortium for Radiologic Imaging Studies of PKD (CRISP;
13 requests); the Acute Renal Failure Trial Network (ATN;
five requests); and the National Analgesic Nephropathy
Study (NANS; two requests). Studies of liver disease and
transplantation were the next most requested data sets
and biospecimens (Table 3).
In addition to the aforementioned requests from external researchers, the Repository also supports ancillary
research by investigators participating in the original
study group or collaborating with them who wish to use
archived biospecimens to address research questions
beyond the funded scope of the original study. As of 9
March 2011, 113 requests have been approved or are pending to provide biospecimens for such ancillary studies.

Sharing non-renewable resources
While digital data sets can be copied ad infinitum, some
biospecimens stored in the Repository are not renewable.
This creates unique challenges. In January 2010, NIDDK
issued a program announcement (PAR-10-090) that was ‘intended to facilitate equitable and appropriate distribution
of biosamples from the NIDDK Central Repositories.’
Investigators requesting nonrenewable biospecimens are
required to consult with the Repository to determine
whether a sufficient quantity of the samples is available
and whether the proposed use of the biospecimens is consistent with the informed consent used in the research
study. Investigators seeking nonrenewable biospecimens
from the Repository are then required to submit an application describing ‘the background and rationale for request; a list of specific objectives; detailed information
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about the proposed studies; detailed information
about the amount and type of samples needed and
documentation from the Repository confirming that
samples are available; plans for sample management;
a description of follow-up plans.’ Requestors are also
required to ‘explain how the proposed research will take
advantage of the large amount of associated phenotypic
data.’

Cost
Maintaining repositories of data and biospecimens is not
cheap, but their costs pale in comparison to the costs of
original data collection. From 2003 to 2013, NIDDK will
spend a total of approximately $73 million for the NIDDK
Repositories (1). Costs are most expensive for archiving
biospecimens ($28 million) and genetic samples ($33 million), while data archiving is less expensive ($12 million).
The costs for acquisition of biosamples has ranged
from $0.70 to $7 per tube while production of DNA or a
cell line and DNA have ranged from $70 to $800.
Maintaining these samples in the Repository has cost
$0.01 per tube per year for biosamples and $10 to $16
per cell line per year.
The cost of the original data collection is, however, much
more expensive. The DCCT-EDIC, for example, has cost
more than $200 million since its inception, while the archiving and distribution costs for genetic samples and immortalized cell lines, biospecimens and multiple data sets have
been less than $3 million.

Expectations for future use
The NIDDK Central Repository was established to improve
the scientific yield of NIDDK-funded research by making
valuable data and specimens available to the wider scientific community. At present, the Repository is being used by
a widening community of researchers, and it is also providing valuable archival services for the original research
teams. We expect that the use of the NIDDK Central
Repository should increase not only with growing
awareness of its resources by the scientific community
but also with the issuance of RFAs for research that
can effectively use this resource. So, for example, NIDDK
solicited grant applications in 2009 to form a multicenter
consortium to ‘discover or validate biomarkers for welldefined human chronic kidney diseases (CKD) (RFA-DK08-015).’ Discovery and testing of candidate biomarkers
requires biological samples (tissues, cells, or body
fluids) from subjects whose disease status has been
well characterized. As the RFA notes, the NIDDK
Central Repository can provide the resources needed for
such research.

Examples of Repository’s impact
on biomedical research
Repository resources have supported a range of biochemical, clinical, statistical and genetic research. Genetic research has included GWAS, validation studies, studies of
Mendelian disease inheritance patterns, studies of genotype–phenotype correlations, development of methods
to improve statistical power of GWAS, and testing of new
statistical methods for genetic research. This research was
spurred by investigators who responded to the 2006 NIDDK
request for applications (RFA-DK-06-005) for ‘applications
that implement large-scale studies and innovative analytical designs using samples from EDIC or GoKinD (or both) to
identify genes and even specific genetic variants that
confer susceptibility or resistance to diabetic complications’.
In addition to facilitating new genetic and biochemical
research using extant biospecimens, the Repository offers
important opportunities for clinical research to scientists
who were not members of the original study teams. They
can request data sets from the Repository to both explore
new and extend prior clinical research. Such ‘secondary
analyses’ serve many important scientific purposes (2),
including insuring efficient use of clinical data produced
by studies that required a large investment of funds and
effort, facilitating replication and extension of the analyses
of the original investigators, and providing a ready resource for inexpensive testing of hypotheses not incorporated in the original study. The latter benefit can be
particularly valuable because it can allow research advances
without the immediate need for new data collection. Such
uses can also provide pilot results that will motivate new
studies—or they may dissuade investigators from pursuing
an unpromising line of future research. By lowering the
cost of entry into a research area, secondary analyses of
archived data can be particularly valuable to junior scientists and others without resources for primary data
collection.
NIH mandates data sharing (3). The Repository supports
that mandate by providing a vehicle for researchers to
access curated and well-maintained archival data sets
and biospecimens and by assisting requestors seeking to
understand these data and specimens. Below we provide
a few examples of biomedical research that has used the
Repository’s resources.

Statistical re-analyses
Using EDIC data archived in the Repository and DCCT data
made available to the public prior to establishment of the
Repository, Kilpatrick and colleagues have published nine
articles that replicate and explore possible extensions
to work reported by the original DCCT/EDIC investigators
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(4–12). The conclusions reached by these investigators
include that:
 Blood glucose variability (within and between days)
does not predict the development of retinopathy or
nephropathy in type 1 diabetics when mean blood glucose is accounted for (7, 8, 11). Longer-term fluctuations in HbA1c, however, may contribute to these
risks (8).
 In addition to HbA1C, mean blood glucose and
within-day blood glucose variability are associated
with risk of hypoglycemia (12).
 Mean blood glucose is a better predictor of cardiovascular risk than HbA1c (5).
 The relationship between mean plasma glucose levels
and HbA1c is not constant. In the DCCT study, subjects
in the conventional treatment condition had consistently higher mean plasma glucose levels than intensively
treated patients at any given level of HbA1c (9).
 Higher levels of insulin resistance (estimated glucose
disposal rate; eGDR) at baseline in DCCT was predictive
of increased risk of retinopathy, nephropathy and cardiovascular complications (10).
Without passing judgment on the relative merits of arguments about these conclusions, we note that the secondary analyses of Kilpatrick and colleagues provided examples
of some of the expected benefits of data sharing. First, as
acknowledged by Kilpatrick himself, the availability of
archived data—among other factors—means that ‘large
grant application success is not always required to perform
meaningful research in [clinical biochemistry]’ (13; p. 28).
None of the DCCT/EDIC articles published by Kilpatrick
and colleagues prior to 2009 reported external funding.
Second, these new analyses of archive data provoked
productive (if sometimes testy) scientific debate (11, 14–
20) as well as re-examination of the original statistical
analyses (21).

Biochemical analyses
The NIDDK Central Repository’s biospecimens have been
used for a variety of biochemical studies including research
in lipidomics, metabolomics and chemoenzymatic analysis.
Ding and colleagues (22), for example, used biospecimens
from the NIDDK Central Repository to apply an accurate
mass and time (AMT) tag approach for a lipidomics analysis
on the plasma, erythrocyte and lymphocyte samples obtained in the Screening for Impaired Glucose Tolerance
(SIGT) project (www.med.emory.edu/research/GCRC/SIGT).
Ding and colleagues’ study concluded that the AMT tag
approach was able to create lipid profiles in different
sample types and detect ‘qualitative and quantitative differences in lipid abundance.’

Genetic research
Nancy Cox, Andrzej Krolewski and Andrew Paterson were
funded under the 2006 RFA and have published a wide
range of findings. Using DCCT/EDIC and GoKinD clinical
and genetic data, they have conducted a series of GWAS.
They have, for example,
 used the DCCT/EDIC sample to discover a major locus
near SORCS1 that was associated with HbA1c and mean
glucose levels in the conventional treatment condition
(23);
 found that multiple variations in SOD1 are associated
with microalbuminuria and serious nephropathy in
DCCT/EDIC subjects (type 1 diabetics) (24);
 found two new loci in UBASH3A and BACH2 that were
associated with type 1 diabetes (25);
 found ELMO1 locus that predicted susceptibility to
diabetic nephropathy in type 1 diabetes mellitus in
the GoKinD study cohort of 820 type 1 diabetes subjects
and 885 control subjects and in 1,304 DCCT/EDIC subjects (26, 27);
 found two loci associated with diabetic nephropathy in
both mice and humans (28); and
 contrary to published results for type 2 diabetes, found
no association between diabetic nephropathy and
‘D18S880 microsatellite and other polymorphisms of
the CNDP2-CNDP1 region’ (29).

Increasing statistical power
The Repository has provided the opportunity for both the
combination of samples to increase statistical power and
for the development and testing of new statistical methods. Barrett and colleagues (30), for example, combined
two previously published genome-wide association analyses of type 1 diabetes involving 1601 cases from the
NIDDK GoKinD study; 1704 controls from the National
Institute of Mental Health (NIMH) study (31); and 5272
cases and controls from the Wellcome Trust Case Control
Consortium (WTCCC) Study (32), along with their own 7982
cases and controls from the NIDDK T1DGC study.
Combining these studies provided improved statistical
power enabling the authors to identify more than 40 loci
associated with type 1 diabetes—with 27 newly identified
regions—after excluding previously reported associations.

Lessons learned as Repository
evolved
Many lessons have been learned in the 8 years of
Repository operation. We offer below four important
lessons that may be of benefit to others who undertake
similar efforts. These lessons involve: the folly of overly ambitious and complex database designs, the need to
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regularly remind coordinating centers of the need to scrupulously maintain and archive linkage files, the benefits of
planning in advance to link study data to the consent documents that specify how these data may be used, and the
value of well-conducted data set integrity checks.

Ambition and complexity
It became clear in the first months of the Repository’s life
that our initial plan was overly ambitious, complex and expensive. Maintaining the archival data (the data that is distributed) in a relational database for flexible processing
was both expensive and unnecessary. If this level of flexibility were needed, it can be readily and (relatively) inexpensively handled by maintaining a database of metadata
that is derived from the archived study data.

Linkage files
Clinical studies typically use one set of subject IDs for internal study purposes, and—as a privacy precaution—
create ‘masked’ IDs when depositing data with the
Repository. While Data Coordinating Centers (DCCs) maintain ‘linkage files’ identifying which study biospecimen IDs
belong to which study subject IDs, the shared data need an
additional linkage file that allows these biospecimen IDs to
be linked to the ‘masked’ IDs. Early in the operations of the
Repository we discovered that some study DCCs did not include such linkage files with the study documentation
when they archived data and biospecimens with the
Repository. The Repository PI and staff undertook a campaign to remind extant and new biospecimen depositors of
the crucial need for accurate and well maintained linkage
files to be deposited along with their biospecimens.

Database of consent documents
Study consent documents are generated by methods that
make them awkward to automate. Typically, they may vary
by study, clinical site, study subpopulation and time interval
and different restrictions may apply to different uses of the
data or biospecimens (e.g. only for use in diabetes research). These consent documents are nonetheless crucial
to Repository operations since they specify the conditions
under which data and biospecimens from a study may be
released.
Inadequate attention was given in Repository planning
to the need for a database of subject consent forms for
each study. At the outset of Repository operations, consent
forms were on file with the sample collection institutions as
well as the NIDDK funding office, but the Repository staff
did not have direct access to these consent forms. In order
to have accountability for data and sample distribution, the
Repository began requesting copies of paper consent forms
from NIDDK. However, storage and retrieval of more than
10,000 multi-page paper consent forms was problematic.
The Repository ultimately created a standalone database

in which to store, upload and retrieve subject consent
forms for each study. This consent form database includes
specific study and site information for each consent form,
disease states and other critical data which are searchable—
plus a PDF of the paper consent forms. This database allows
secure access to consent forms by Repository staff and the
NIDDK funding office, and it helps ensure that only samples
and data which were ‘approved for sharing’ and approved
for particular ‘types’ of research are shared.
Development of the consent database required a sustained effort during normal Repository operations to separate, scan and assign filenames for each paper consent
form by study and collection site, and then to enter into
the database the relevant data from each consent form
including; approval and expiration dates, disease state(s),
exceptions to sharing, plus ‘approved only for specific research’ and ‘not approved for genetic research’ restrictions.
This was hardly an optimal solution. If the need for such a
consent database had been better anticipated, we would
have conducted a comprehensive review of the information
and design requirements for a consent database immediately upon award of the Repository contract. A ‘consent
forms database’ would then have been developed in
conjunction with the data and biospecimen databases.
The resultant consent forms database would have been
co-located in the main database and accessible alongside
of and linked to the sample data instead of adjacent to the
sample data.

Data set integrity checks
As a partial check of the integrity of the data sets archived
in the NIDDK data Repository, prior to data release, we
perform a set of tabulations and statistical analyses to
verify that published results from the study can be reproduced using our archived data sets. The intent of these data
set integrity checks is to provide confidence that the data
sets distributed by the NIDDK Repository is a true copy of
the study data. These analyses have helped us avoid serious
problems including, for example, distribution of data sets
that were missing a sizable number of cases and distribution of data sets that included subsamples of subjects who
had refused consent for data distribution beyond the original study team.

Future Repository enhancements
We anticipate that the future impact on disease research of
the studies archived in the Repository will be enhanced by:
(i) cross-listing of Repository biospecimens in other searchable databases; (ii) roll out of a suite of applications for
querying the contents of the Repository; and (iii) over
time, an increased harmonization of procedures, data collection strategies, questionnaires etc. across both research
studies and within the vocabularies used by different
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repositories (see e.g. the DataSHaPER tools for harmonization developed by the P3G network; see www.datashaper
.org/).

Cross-listing of resources
To make the Repository resources visible to a broad user
community, our available biospecimens are listed in the
catalogs of other biobanks. Currently, we list approximately
500 000 biospecimens of six sample types for five diseases in
the NIH Office of Rare Diseases Research Biospecimens/
Biorepositories Rare Disease-HUB (RD-HUB). Biospecimens
from four studies of renal diseases (total of 6855 subjects)
are listed in the P3G Renal Biobank and biospecimens from
one diabetes study (3075 subjects) are listed in the P3G
Diabetes Biobank. The biospecimen resources of these partner biobanks are also cross-listed at the Repository Website
under ‘Related Websites’ (see www.niddkrepository.org/
niddk/jsp/public/websites.jsp). The Repository plans to
expand our efforts to cross-list study biospecimens in a
wide range of biobanks catalogs.
We are also in the process of registering the Repository
as a biobank within the Common Biorepository Model
(CBM) network (see: cabig.nci.nih.gov/workspaces/TBPT/
CBM/). This will permit the NIDDK Central Repository to
be accessible using the NCI Specimen Resource Locator
(SRL)—a service that allows researchers to locate human
biospecimens (tissue, serum, DNA/RNA, other specimens)
for their research.

Query tools
The need for adequate tools to search the expanding contents of the NIDDK Repository was recognized in our initial
proposal. The simplification of the Repository’s design at its
birth required both a different suite of search tools and
more time to understand our users’ needs and to develop
the require tools. The slow accretion of studies in the archive’s early years also diminished the urgency of the need for
such tools. Below we briefly describe both our initial plan
and the search tools that are currently being rolled out.

2002 plan. We initially planned to establish cross–
reference relationships between specific fields from
multiple study databases, and to create translation
tables to standardize similar field values into a single
code and description. These translation tables would
have been separate from the study tables and might
be created using data dictionaries and/or code books. The
following tables are an example of the planned translation
tables:
 tblCategory—general category area of interest
 tblStandardText—specific standardized text under a
general category

 tblTranslation—creates
a
relationship
between
tblStandardData and specific fields in study tables
These translation tables would standardize the criteria
used in the search requests on similar fields across all
study databases. This methodology would also eliminate
the need to know the synonyms for similar fields across
studies. Where possible, we anticipated that semantically
equivalent fields in different databases would be identified
in advance of any data requests on study databases. We
expected that all finished databases in the Repository
would be reviewed to identify fields that match existing
relationships. As the translation tables grow, we expected
this search and cross–reference capacity of the search interface will increase.
This planned search strategy was abandoned when we
choose to simplify the Repository design (see ‘Revision of
Design’ section).

Current query tools. To provide a search capability for
the current Repository, we are rolling out a suite of applications referred to as the public query tool (PQT). To provide greater flexibility and enhance searching capabilities
for the user, we developed a series of publicly accessible
query tools whose main intent was to address the question,
‘What’s in the NIDDK Central Data Repository (CDR)?’.
The PQT provides public viewers/users of the contents of
the CDR with an easy to use interface that supports a
wide variety of user interests (e.g. what studies have
family history data for Type I diabetes and/or contain a
minimum of 150 African-American subjects older than 50
years of age). The PQT includes four distinct search engine
tools.
The first tool—the Keyword Metadata Search tool—
allows users to select keywords from drop down menus
that identify the studies with those specific features.
The keywords are obtained from study specific metadata
examples of which include diagnosis and type of study. The
tool searches the metadata to define studies that link to
the keywords. Users who are not familiar can quickly identify studies with a variety of useful properties. No specific
knowledge of the studies is required to use this tool which
is currently available on the website.
The second tool—the Ontology based keyword search
engine—uses study variables that have been identified as
scientifically important. To support this and the other tools
below, variables of scientific interest have been extracted
from the data archive (into a curated database) and can be
accessed by the tools. In the case of the Ontology tool, it is
designed to search ‘free text’ keywords provided by the
user as contrasted with structured text from ‘drop down’
controls used by the basic search tool. The user supplied key
words will link to an ontology that has been mapped to the
curated database. The keywords will use the mappings to
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identify studies that exhibit the traits implied by the
keywords.
The third tool—codebook variable engine—will allow a
user to highlight a study and the important variables that
have been included in the curated database. Each variable
included in the list can be ‘clicked’ to generate a variable
description and an associated set of frequencies.
The fourth tool—the crosstab tool—will allows users to
obtain crosstabulations both within and across specified
studies. Such crosstabulations will allow users to identify,
for example, studies that have 35 or more African American
subjects that survived liver transplants for a minimum of
5 years; or to learn before requesting study data whether
a given study has at least 50 subjects between the ages of
40 and 60 with fasting glucose or 140 mg/dl or higher.
Our tools are intended to represent three perspectives:
(1) A Study perspective that identifies specific traits that
identify the purpose of the study, its principal findings
and the main design elements. These elements would
include design elements and/or treatment features
that might provide insights for the design of new
studies, using existing studies as a starting point.
(2) The disease domain perspective identifies data across
a variety of clinical sources that present a unified view
of individual patients within a specific disease domain
that have different protocols. This user is interested in
viewing studies administered by different protocols
that are about the same disease type. From this perspective data from multiple studies are linked and
pooled (if possible) for a reexamination of the underlying and undiscovered properties related to a disease
and the treatment of that disease. The data represented by his perspective will identify features of
the severity disease. These variables may include
serum creatinine levels (for the kidney disease
domain), disease confounders (e.g. blood pressure
and age, diet and lifestyle) and primary diseaserelated outcomes from multiple studies within a
given disease domain. The potential for linking multiple studies with common data elements within a disease domain is an important feature from the
perspective of this user.
(3) A common data element perspective that uses data
with broad level attributes for the purpose of comparing all types of clinical studies from a common set
of measures (i.e. age, gender, diagnosis does genotype data exist? Is medical history available?).
This level will include data elements defined by the
NCI Common Biorepository Model (CBM). There
are 30 variables in the CBM (cabig.nci.nih.gov/
workspaces/TBPT/CBM/). We will include all 30 variables for each NIDDK study in the Repository. All
CBM variables will be harmonized to a standard set

of ontologies that are included in the Cancer
Biomedical Informatics Grid (caBIG) (see cabig.nci.nih
.gov/workspaces/VCDE).

Increased harmonization
While good query tools are extremely helpful, there is
no substitute for the use of a universal set of standards
during the study design phase that incorporates a standard
vocabulary and nomenclature into the design process.
Potentially useful coding systems include:
 Logical Observation Identifiers Name and Code (LOINC)
used in diagnostic reports, survey instruments, laboratory tests and clinical measurements (loinc.org/) and
 Systemized Nomenclature of Medicine—Clinical Terms
(SNOMED) used to assign codes for organisms, anatomic
parts, specimens, diagnoses and symptoms (www.nlm
.nih.gov/research/umls/Snomed/snomed_main.html).
However, most legacy studies have not incorporated
such standards into their design. Considerable efforts are
under way to standardize both procedures and terminology in biomedical research, with special attention to studies that will provide data and biospecimens for secondary
analysis. The ability to pool data is crucially dependent
on the equivalence of research methods used to obtain
and store data and biospecimens. The ability to discover
common data elements across studies, in turn, depends
upon the use of a standard vocabulary or the development
of automated thesauruses that permit identification
of potentially equivalent measurements or specimens.
Standardizing procedures and terminology will provide important benefits, but standardizing variable measurements
will be a major endeavor that will require both substantial
time and resources to complete. Such harmonization efforts are, however, crucial to increasing the usage and realizing the full scientific value of the NIDDK Central
Repository and other data and biobanks. Current efforts
by others include the P3G DataSHaPER (33), Phoenix (34,
35) and the CBM (cabig.nci.nih.gov/workspaces/TBPT/CBM/).

Conclusion
The NIDDK Central Repository was established to increase
the impact of valuable data and biospecimens by making
these materials available to the broader scientific community. The available evidence suggests that the Repository is
beginning to fulfill this promise. Development of new bioinformatic tools to query the availability of data or biospecimens within the Repository together with the expanding
reputation of the Repository and ongoing harmonization
efforts should lead to increased use of this valuable
resource.
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